SBIR Phase I: Immunity Transfer by Magnetic Separation (COVID-19)

此小企业创新研究（SBIR）第一阶段项目的更广泛影响/商业潜力针对COVID-19全球大流行。最近，从COVID-19康复患者中输注血浆已显示出一定的治疗效果。这是由于供体血浆中的抗体识别SARS-CoV-2病毒，增强了受体的免疫系统，以更好地对抗COVID-19。通过将供体血浆与涂有可以捕获这些治疗性抗体的分子的磁性颗粒混合，我们将磁性提取、纯化和浓缩这些抗体，用于COVID-19治疗。这项技术也可以扩展到其他疾病。 这个小型企业创新研究第一阶段项目提出开发化学缀合策略和新型磁体阵列，能够从每个单位的血浆中分离出大量的治疗性抗体。该策略引入了从单个康复的COVID-19患者中收获大量治疗性SARS-CoV-2抗体的潜力，使得能够从一个康复患者的血浆中治疗多个患者。抗体耗尽的血浆可以返回给供体，使得能够进行多次血浆捐献，而不需要从供体永久地移除血浆。此外，获得纯化的抗体应该能够扩大治疗剂量，可能赋予更长的免疫力或诱导患者更强大的免疫反应。该奖项反映了NSF的法定使命，并已被认为值得通过使用基金会的智力价值和更广泛的影响审查标准进行评估的支持。

The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase I project addresses the COVID-19 global pandemic. Recently, transfusions of plasma from recovered COVID-19 patients has shown some efficacy in treatment. This is due to antibodies in the donor plasma that recognize the SARS-CoV-2 virus, boosting the recipient’s immune system to better fight COVID-19. By mixing donor plasma with magnetic particles coated with molecules that can capture these therapeutic antibodies, we will magnetically extract, purify and concentrate these antibodies for use in COVID-19 treatment. This technology can potentially be extended to other diseases as well. This Small Business Innovation Research Phase I project proposes to develop chemical conjugation strategies and novel magnet arrays capable of isolating large amounts of therapeutic antibody from each unit of plasma. This strategy introduces the potential to harvest large amounts of therapeutic SARS-CoV-2 antibodies from a single recovered COVID-19 patient, enabling treatment of multiple patients from the plasma of one convalescent patient. The antibody-depleted plasma can be returned to the donor, enabling multiple plasma donations without the requirement of permanently removing plasma from the donor. In addition, access to purified antibodies should enable scaling of the therapeutic dose, potentially conferring longer immunity or inducing a more robust immune response in the patient.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.